diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM13106diaendo-13106Research ArticleОбзорыReviewВлияние инновационных сахароснижающих препаратов на течение и исход COVID-19 у пациентов с сахарным диабетом 2 типаThe impact of innovative glucose-lowering drugs on the course and outcome of COVID-19 in patients with type 2 diabetes mellitushttps://orcid.org/0000-0001-7911-2424МарковаТ. Н.MarkovaT. N.

Маркова Татьяна Николаевна - д.м.н., профессор.

Москва

Tatyana N. Markova - MD, PhD, Professor.

Moscow

markovatn18@yandex.ruhttps://orcid.org/0000-0002-9498-6039СтасМ. С.StasM. S.

Стас Мухамед Самих - аспирант.

127473, Москва, ул. Делегатская, д. 20, стр. 1

Mukhamed S. Stas, MD, PhD student.

20, p. 1, Delegatskaya street, 127473 Moscow

hamudestas@gmail.comРоссийский университет медицины; Городская клиническая больница № 52РоссияRussian University of Medicine; Moscow City Clinical Hospital 52Russian FederationРоссийский университет медициныРоссияRussian University of MedicineRussian Federation202406052024272174184Copyright © Маркова Т.Н., Стас М.С., 20242024Маркова Т.Н., Стас М.С.Markova T.N., Stas M.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/13106

Пациенты с сахарным диабетом 2 типа (СД2) находятся в группе высокого риска неблагоприятных исходов при коронавирусной инфекции (COVID-19). Несмотря на постепенное разрешение пандемии, появляются новые штаммы вируса, характеризующиеся высокой контагиозностью, и увеличивается риск перехода инфекции в сезонное заболевание. В связи чем остается актуальным вопрос выявления факторов риска, утяжеляющих течение COVID-19 у больных с СД2, в том числе роль исходной сахароснижающей терапии.

В обзоре представлена и систематизирована актуальная информация (по данным рандомизированных клинических испытаний и метаанализов) о влиянии амбулаторного и стационарного применения метформина и инновационных сахароснижающих препаратов (агонисты рецепторов глюкагоноподобного пептида-1, ингибиторы натрий-глюкозного котранспортера 2-го типа, ингибиторы дипептидилпептидазы-4) на течение и исход COVID-19 у пациентов с СД2. При этом описаны потенциальные механизмы реализации патогенетического воздействия препаратов на течение COVID-19, положительные и отрицательные аспекты их назначения.

Patients with type 2 diabetes mellitus (T2DM) are at high risk of adverse outcomes in coronavirus infection (COVID-19). Despite the gradual resolution of the pandemic, new strains of the virus are emerging, characterized by high contagiousness, and the risk of infection becoming a seasonal disease is increasing. In this connection, the issue of identifying risk factors that aggravate the course of COVID-19 in patients with T2DM, including the role of initial hypoglycemic therapy, remains relevant.

The review presents and systematizes up-to-date information (according to randomized clinical trials and meta-analyses) on the effect of outpatient and inpatient use of metformin and innovative hypoglycemic drugs (glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors) on the course and outcome of COVID-19 in patients with T2DM. At the same time, the potential mechanisms of the pathogenetic effect of drugs on the course of COVID-19, positive and negative aspects of their administration are described.

COVID-19сахарный диабет 2 типаметформинагонисты рецепторов глюкагоноподобного пептида-1ингибиторы натрий-глюкозного котранспортера 2-го типаингибиторы дипептидилпептидазы-4COVID-19type 2 diabetes mellitusmetforminglucagon-like peptide-1 receptor agonistssodium-glucose cotransporter-2 inhibitorsdipeptidyl peptidase-4 inhibitorsРабота выполнена по инициативе авторов без привлечения финансированияReferencesWorld Health Organization [Internet]. Available at: https://www.who.int/ru/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020World Health Organization [Internet]. Available at: https://www.who.int/ru/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020World Health Organization [Internet]. Available at: https://www.who.int/ru/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemicWorld Health Organization [Internet]. Available at: https://www.who.int/ru/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemicWorld Health Organization [Internet]. Available at: https://www.who.int/docs/default-source/coronaviruse/09082023eg.5_ire_final.pdf?sfvrsn=2aa2daee_1World Health Organization [Internet]. Available at: https://www.who.int/docs/default-source/coronaviruse/09082023eg.5_ire_final.pdf?sfvrsn=2aa2daee_1Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека [интернет]. Доступно по: https://www.rospotrebnadzor.ru/about/info/news/news_details.php?ELEMENT_ID=25928&sphrase_id=5063415Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека [интернет]. Доступно по: https://www.rospotrebnadzor.ru/about/info/news/news_details.php?ELEMENT_ID=25928&sphrase_id=5063415Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet. 2020;395(10229):1038] [published correction appears in Lancet. 2020;395(10229):1038]. Lancet. 2020;395(10229):1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet. 2020;395(10229):1038] [published correction appears in Lancet. 2020;395(10229):1038]. Lancet. 2020;395(10229):1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3Маркова Т.Н., Пономарева А.А., Самсонова И.В., и др. Факторы риска летального исхода у больных сахарным диабетом 2 типа и новой коронавирусной инфекцией. Эндокринология: Новости. Мнения. Обучение. 2022. — Т.1. — №38. — С. 8-16. https://doi.org/10.33029/2304-9529-2022-11-1-8-16Markova TN, Ponomareva AA, Samsonova IV, et al. Risk factors for fatal outcome in patients with type 2 diabetes mellitus and a new coronavirus infection. Endokrinologiya: novosti, mneniya, obuchenie. 2022;11(1):8–16. (in Russ). https://doi.org/10.33029/2304-9529-2022-11-1-8-16Roncon L, Zuin M, Rigatelli G, Zuliani G. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. J Clin Virol. 2020;127:104354. https://doi.org/10.1016/j.jcv.2020.104354Roncon L, Zuin M, Rigatelli G, Zuliani G. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. J Clin Virol. 2020;127:104354. https://doi.org/10.1016/j.jcv.2020.104354MCCarthy MW. Metformin as a potential treatment for COVID-19. Expert Opin Pharmacother. 2023;24(10):1199-1203. https://doi.org/10.1080/14656566.2023.2215385MCCarthy MW. Metformin as a potential treatment for COVID-19. Expert Opin Pharmacother. 2023;24(10):1199-1203. https://doi.org/10.1080/14656566.2023.2215385Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583(7816):459-468. https://doi.org/10.1038/s41586-020-2286-9Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583(7816):459-468. https://doi.org/10.1038/s41586-020-2286-9Sun X, Liu Y, Huang Z, et al. SARS-CoV-2 non-structural protein 6 triggers NLRP3-dependent pyroptosis by targeting ATP6AP1. Cell Death Differ. 2022;29(6):1240-1254. https://doi.org/10.1038/s41418-021-00916-7Sun X, Liu Y, Huang Z, et al. SARS-CoV-2 non-structural protein 6 triggers NLRP3-dependent pyroptosis by targeting ATP6AP1. Cell Death Differ. 2022;29(6):1240-1254. https://doi.org/10.1038/s41418-021-00916-7Schaller MA, Sharma Y, Dupee Z, et al. Ex vivo SARS-CoV-2 infection of human lung reveals heterogeneous host defense and therapeutic responses. JCI Insight. 2021;6(18):e148003. https://doi.org/10.1172/jci.insight.148003Schaller MA, Sharma Y, Dupee Z, et al. Ex vivo SARS-CoV-2 infection of human lung reveals heterogeneous host defense and therapeutic responses. JCI Insight. 2021;6(18):e148003. https://doi.org/10.1172/jci.insight.148003Xian H, Liu Y, Rundberg Nilsson A, et al. Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation. Immunity. 2021;54(7):1463-1477.e11. https://doi.org/10.1016/j.immuni.2021.05.004Xian H, Liu Y, Rundberg Nilsson A, et al. Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation. Immunity. 2021;54(7):1463-1477.e11. https://doi.org/10.1016/j.immuni.2021.05.004Cory TJ, Emmons RS, Yarbro JR, et al. Metformin Suppresses Monocyte Immunometabolic Activation by SARS-CoV-2 Spike Protein Subunit 1. Front Immunol. 2021;12:733921. https://doi.org/10.3389/fimmu.2021.733921Cory TJ, Emmons RS, Yarbro JR, et al. Metformin Suppresses Monocyte Immunometabolic Activation by SARS-CoV-2 Spike Protein Subunit 1. Front Immunol. 2021;12:733921. https://doi.org/10.3389/fimmu.2021.733921Chen S, Han Y, Yang L, et al. SARS-CoV-2 Infection Causes Dopaminergic Neuron Senescence. Preprint. Res Sq. 2021;rs.3.rs-513461. Published 2021 May 21. https://doi.org/10.21203/rs.3.rs-513461/v1Chen S, Han Y, Yang L, et al. SARS-CoV-2 Infection Causes Dopaminergic Neuron Senescence. Preprint. Res Sq. 2021;rs.3.rs-513461. Published 2021 May 21. https://doi.org/10.21203/rs.3.rs-513461/v1Parthasarathy H, Tandel D, Siddiqui AH, Harshan KH. Metformin suppresses SARS-CoV-2 in cell culture [published online ahead of print, 2022 Nov 20]. Virus Res. 2022;323:199010. https://doi.org/10.1016/j.virusres.2022.199010Parthasarathy H, Tandel D, Siddiqui AH, Harshan KH. Metformin suppresses SARS-CoV-2 in cell culture [published online ahead of print, 2022 Nov 20]. Virus Res. 2022;323:199010. https://doi.org/10.1016/j.virusres.2022.199010Ventura-López C, Cervantes-Luevano K, Aguirre-Sánchez JS, et al. Treatment with metformin glycinate reduces SARS-CoV-2 viral load: An in vitro model and randomized, double-blind, Phase Iib clinical trial. Biomed Pharmacother. 2022;152:113223. https://doi.org/10.1016/j.biopha.2022.113223Ventura-López C, Cervantes-Luevano K, Aguirre-Sánchez JS, et al. Treatment with metformin glycinate reduces SARS-CoV-2 viral load: An in vitro model and randomized, double-blind, Phase Iib clinical trial. Biomed Pharmacother. 2022;152:113223. https://doi.org/10.1016/j.biopha.2022.113223Bramante CT, Huling JD, Tignanelli CJ, et al. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. N Engl J Med. 2022;387(7):599-610. https://doi.org/10.1056/NEJMoa2201662Bramante CT, Huling JD, Tignanelli CJ, et al. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. N Engl J Med. 2022;387(7):599-610. https://doi.org/10.1056/NEJMoa2201662Reis G, Dos Santos Moreira Silva EA, Medeiros Silva DC, et al. Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial. Lancet Reg Health Am. 2022;6:100142. https://doi.org/10.1016/j.lana.2021.100142Reis G, Dos Santos Moreira Silva EA, Medeiros Silva DC, et al. Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial. Lancet Reg Health Am. 2022;6:100142. https://doi.org/10.1016/j.lana.2021.100142Nassar M, Abosheaishaa H, Singh AK, et al. Noninsulin-based antihyperglycemic medications in patients with diabetes and COVID-19: A systematic review and meta-analysis. J Diabetes. 2023;15(2):86-96. https://doi.org/10.1111/1753-0407.13359Nassar M, Abosheaishaa H, Singh AK, et al. Noninsulin-based antihyperglycemic medications in patients with diabetes and COVID-19: A systematic review and meta-analysis. J Diabetes. 2023;15(2):86-96. https://doi.org/10.1111/1753-0407.13359Ganesh A, Randall MD. Does metformin affect outcomes in COVID-19 patients with new or pre-existing diabetes mellitus? A systematic review and meta-analysis. Br J Clin Pharmacol. 2022;88(6):2642-2656. https://doi.org/10.1111/bcp.15258Ganesh A, Randall MD. Does metformin affect outcomes in COVID-19 patients with new or pre-existing diabetes mellitus? A systematic review and meta-analysis. Br J Clin Pharmacol. 2022;88(6):2642-2656. https://doi.org/10.1111/bcp.15258Nguyen NN, Ho DS, Nguyen HS, et al. Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis. Metabolism. 2022;131:155196. https://doi.org/10.1016/j.metabol.2022.155196Nguyen NN, Ho DS, Nguyen HS, et al. Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis. Metabolism. 2022;131:155196. https://doi.org/10.1016/j.metabol.2022.155196Zhan K, Weng L, Qi L, et al. Effect of Antidiabetic Therapy on Clinical Outcomes of COVID-19 Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis. Ann Pharmacother. 2023;57(7):776-786. https://doi.org/10.1177/10600280221133577Zhan K, Weng L, Qi L, et al. Effect of Antidiabetic Therapy on Clinical Outcomes of COVID-19 Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis. Ann Pharmacother. 2023;57(7):776-786. https://doi.org/10.1177/10600280221133577Ma Z, Krishnamurthy M. Is metformin use associated with low mortality in patients with type 2 diabetes mellitus hospitalized for COVID-19? A multivariable and propensity score-adjusted meta-analysis. PloS One. 2023;18(2):e0282210. https://doi.org/10.1371/journal.pone.0282210Ma Z, Krishnamurthy M. Is metformin use associated with low mortality in patients with type 2 diabetes mellitus hospitalized for COVID-19? A multivariable and propensity score-adjusted meta-analysis. PloS One. 2023;18(2):e0282210. https://doi.org/10.1371/journal.pone.0282210Han T, Ma S, Sun C, et al. Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis. Arch Med Res. 2022;53(2):186-195. https://doi.org/10.1016/j.arcmed.2021.08.002Han T, Ma S, Sun C, et al. Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis. Arch Med Res. 2022;53(2):186-195. https://doi.org/10.1016/j.arcmed.2021.08.002Chen Y, Lv X, Lin S, Arshad M, Dai M. The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis. Front Endocrinol (Lausanne). 2022;13:895458. https://doi.org/10.3389/fendo.2022.895458Chen Y, Lv X, Lin S, Arshad M, Dai M. The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis. Front Endocrinol (Lausanne). 2022;13:895458. https://doi.org/10.3389/fendo.2022.895458Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al; on behalf of the American Diabetes Association, Introduction and Methodology: Standards of Care in Diabetes—2023. Diabetes Care 1 January 2023; 46 (Supplement_1): S1–S4. https://doi.org/10.2337/dc23-SintNuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al; on behalf of the American Diabetes Association, Introduction and Methodology: Standards of Care in Diabetes—2023. Diabetes Care 1 January 2023; 46 (Supplement_1): S1–S4. https://doi.org/10.2337/dc23-SintMarx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-4140. https://doi.org/10.1093/eurheartj/ehad192Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-4140. https://doi.org/10.1093/eurheartj/ehad192Мкртумян А.М., Маркова Т.Н., Мищенко Н.К. Кардиопротективные механизмы ингибиторов натрий-глюкозного котранспортера 2 типа // Сахарный диабет. 2021. — Т. 24. — №3. — С. 291-299. https://doi.org/10.14341/DM12541Mkrtumyan AM, Markova TN, Mishchenko NK. Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors. Diabetes mellitus. 2021;24(3):291-299. (In Russ.) https://doi.org/10.14341/DM12541Patoulias D, Papadopoulos C, Boulmpou A, Doumas M. Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the COVID-19 pandemic. Diabetes Obes. Metab. 2021;23:1696–1700. https://doi.org/10.1111/dom.14359Patoulias D, Papadopoulos C, Boulmpou A, Doumas M. Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the COVID-19 pandemic. Diabetes Obes. Metab. 2021;23:1696–1700. https://doi.org/10.1111/dom.14359Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: From pathophysiology to clinical management. Nat. Rev. Endocrinol. 2021;17:11–30. https://doi.org/10.1038/s41574-020-00435-4Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: From pathophysiology to clinical management. Nat. Rev. Endocrinol. 2021;17:11–30. https://doi.org/10.1038/s41574-020-00435-4Katsiki N, Ferrannini E. Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era? J. Diabetes Complicat. 2020;34:107723. https://doi.org/10.1016/j.jdiacomp.2020.107723Katsiki N, Ferrannini E. Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era? J. Diabetes Complicat. 2020;34:107723. https://doi.org/10.1016/j.jdiacomp.2020.107723Kosiborod M, Berwanger O, Koch GG, et al. Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study. Diabetes Obes. Metab. 2021;23:886–896. https://doi.org/10.1111/dom.14296Kosiborod M, Berwanger O, Koch GG, et al. Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study. Diabetes Obes. Metab. 2021;23:886–896. https://doi.org/10.1111/dom.14296Kosiborod MN, Esterline R, Furtado RHM, et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;9(9):586-594. https://doi.org/10.1016/S2213-8587(21)00180-7Kosiborod MN, Esterline R, Furtado RHM, et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;9(9):586-594. https://doi.org/10.1016/S2213-8587(21)00180-7Permana H, Audi Yanto T, Ivan Hariyanto T. Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression. Diabetes Res Clin Pract. 2023;195:110205. https://doi.org/10.1016/j.diabres.2022.110205Permana H, Audi Yanto T, Ivan Hariyanto T. Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression. Diabetes Res Clin Pract. 2023;195:110205. https://doi.org/10.1016/j.diabres.2022.110205Zhu Z, Zeng Q, Liu Q, Wen J, Chen G. Association of Glucose-Lowering Drugs With Outcomes in Patients With Diabetes Before Hospitalization for COVID-19: A Systematic Review and Network Meta-analysis. JAMA Netw Open. 2022;5(12):e2244652. https://doi.org/10.1001/jamanetworkopen.2022.44652Zhu Z, Zeng Q, Liu Q, Wen J, Chen G. Association of Glucose-Lowering Drugs With Outcomes in Patients With Diabetes Before Hospitalization for COVID-19: A Systematic Review and Network Meta-analysis. JAMA Netw Open. 2022;5(12):e2244652. https://doi.org/10.1001/jamanetworkopen.2022.44652Schlesinger S, Lang A, Christodoulou N, et al. Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis. Diabetologia. 2023;66(8):1395-1412. https://doi.org/10.1007/s00125-023-05928-1Schlesinger S, Lang A, Christodoulou N, et al. Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis. Diabetologia. 2023;66(8):1395-1412. https://doi.org/10.1007/s00125-023-05928-1Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-1705. https://doi.org/10.1016/S0140-6736(06)69705-5Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-1705. https://doi.org/10.1016/S0140-6736(06)69705-5Klemann C, Wagner L, Stephan M, von Hörsten S. Cut to the chase: a review of CD26/dipeptidyl peptidase-4’s (DPP4) entanglement in the immune system. Clin Exp Immunol. 2016;185(1):1-21. https://doi.org/10.1111/cei.12781Klemann C, Wagner L, Stephan M, von Hörsten S. Cut to the chase: a review of CD26/dipeptidyl peptidase-4’s (DPP4) entanglement in the immune system. Clin Exp Immunol. 2016;185(1):1-21. https://doi.org/10.1111/cei.12781Shao S, Xu Q, Yu X, Pan R, Chen Y. Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions. Pharmacol Ther. 2020;209:107503. https://doi.org/10.1016/j.pharmthera.2020.107503Shao S, Xu Q, Yu X, Pan R, Chen Y. Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions. Pharmacol Ther. 2020;209:107503. https://doi.org/10.1016/j.pharmthera.2020.107503Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020;27(5):1451-1454. https://doi.org/10.1038/s41418-020-0530-3Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020;27(5):1451-1454. https://doi.org/10.1038/s41418-020-0530-3Chen CF, Chien CH, Yang YP, et al. Role of dipeptidyl peptidase-4 inhibitors in patients with diabetes infected with coronavirus-19. J Chin Med Assoc. 2020;83(8):710-711. https://doi.org/10.1097/JCMA.0000000000000338Chen CF, Chien CH, Yang YP, et al. Role of dipeptidyl peptidase-4 inhibitors in patients with diabetes infected with coronavirus-19. J Chin Med Assoc. 2020;83(8):710-711. https://doi.org/10.1097/JCMA.0000000000000338Abuhasira R, Ayalon-Dangur I, Zaslavsky N, et al. A Randomized Clinical Trial of Linagliptin vs. Standard of Care in Patients Hospitalized With Diabetes and COVID-19. Front Endocrinol (Lausanne). 2021;12:794382. https://doi.org/10.3389/fendo.2021.794382Abuhasira R, Ayalon-Dangur I, Zaslavsky N, et al. A Randomized Clinical Trial of Linagliptin vs. Standard of Care in Patients Hospitalized With Diabetes and COVID-19. Front Endocrinol (Lausanne). 2021;12:794382. https://doi.org/10.3389/fendo.2021.794382Guardado-Mendoza R, Garcia-Magaña MA, Martínez-Navarro LJ, et al. Effect of linagliptin plus insulin in comparison to insulin alone on metabolic control and prognosis in hospitalized patients with SARS-CoV-2 infection. Sci Rep. 2022;12(1):536. https://doi.org/10.1038/s41598-021-04511-1Guardado-Mendoza R, Garcia-Magaña MA, Martínez-Navarro LJ, et al. Effect of linagliptin plus insulin in comparison to insulin alone on metabolic control and prognosis in hospitalized patients with SARS-CoV-2 infection. Sci Rep. 2022;12(1):536. https://doi.org/10.1038/s41598-021-04511-1Zein AFMZ, Raffaello WM. Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 — A systematic review and meta-analysis. Prim Care Diabetes. 2022;16(1):162-167. https://doi.org/10.1016/j.pcd.2021.12.008Zein AFMZ, Raffaello WM. Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 — A systematic review and meta-analysis. Prim Care Diabetes. 2022;16(1):162-167. https://doi.org/10.1016/j.pcd.2021.12.008Abudalo RA, Alqudah AM, Roarty C, Athamneh RY, Grieve DJ. Oxidative stress and inflammation in COVID-19: potential application OF GLP-1 receptor agonists. Eur Rev Med Pharmacol Sci. 2023;27(13):6459-6471. https://doi.org/10.26355/eurrev_202307_33007Abudalo RA, Alqudah AM, Roarty C, Athamneh RY, Grieve DJ. Oxidative stress and inflammation in COVID-19: potential application OF GLP-1 receptor agonists. Eur Rev Med Pharmacol Sci. 2023;27(13):6459-6471. https://doi.org/10.26355/eurrev_202307_33007Banerjee Y, Pantea Stoian A, Silva-Nunes J, et al. The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism. Expert Opin Drug Saf. 2021;20(11):1309-1315. https://doi.org/10.1080/14740338.2021.1970744Banerjee Y, Pantea Stoian A, Silva-Nunes J, et al. The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism. Expert Opin Drug Saf. 2021;20(11):1309-1315. https://doi.org/10.1080/14740338.2021.1970744Lee JH. Potential therapeutic effect of glucagon-like peptide-1 receptor agonists on COVID-19-induced pulmonary arterial hypertension. Med Hypotheses. 2022;158:110739. https://doi.org/10.1016/j.mehy.2021.110739Lee JH. Potential therapeutic effect of glucagon-like peptide-1 receptor agonists on COVID-19-induced pulmonary arterial hypertension. Med Hypotheses. 2022;158:110739. https://doi.org/10.1016/j.mehy.2021.110739Ishigaki Y, Strizek A, Aranishi T, et al. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57). Diabetes Ther. 2021;12(1):345-361. https://doi.org/10.1007/s13300-020-00977-wIshigaki Y, Strizek A, Aranishi T, et al. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57). Diabetes Ther. 2021;12(1):345-361. https://doi.org/10.1007/s13300-020-00977-wBray JJH, Foster-Davies H, Salem A, et al. Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomised controlled trials. Diabetes Obes Metab. 2021 Aug;23(8):1806-1822. https://doi.org/10.1111/dom.14399Bray JJH, Foster-Davies H, Salem A, et al. Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomised controlled trials. Diabetes Obes Metab. 2021 Aug;23(8):1806-1822. https://doi.org/10.1111/dom.14399Helmstädter J, Frenis K, Filippou K, et al. Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension. Arterioscler Thromb Vasc Biol. 2020;40(1):145-158. https://doi.org/10.1161/atv.0000615456.97862.30Helmstädter J, Frenis K, Filippou K, et al. Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension. Arterioscler Thromb Vasc Biol. 2020;40(1):145-158. https://doi.org/10.1161/atv.0000615456.97862.30Wang R, Lu L, Guo Y, et al. Effect of Glucagon-like Peptide-1 on High-Glucose-induced Oxidative Stress and Cell Apoptosis in Human Endothelial Cells and Its Underlying Mechanism. J Cardiovasc Pharmacol. 2015;66(2):135-140. https://doi.org/10.1097/FJC.0000000000000255Wang R, Lu L, Guo Y, et al. Effect of Glucagon-like Peptide-1 on High-Glucose-induced Oxidative Stress and Cell Apoptosis in Human Endothelial Cells and Its Underlying Mechanism. J Cardiovasc Pharmacol. 2015;66(2):135-140. https://doi.org/10.1097/FJC.0000000000000255Barale C, Buracco S, Cavalot F, et al. Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation. Thromb Haemost. 2017;117(6):1115-1128. https://doi.org/10.1160/TH16-07-0586Barale C, Buracco S, Cavalot F, et al. Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation. Thromb Haemost. 2017;117(6):1115-1128. https://doi.org/10.1160/TH16-07-0586Bułdak Ł, Łabuzek K, Bułdak RJ, et al. Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages. Naunyn Schmiedebergs Arch Pharmacol. 2015;388(9):905-919. https://doi.org/10.1007/s00210-015-1124-3Bułdak Ł, Łabuzek K, Bułdak RJ, et al. Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages. Naunyn Schmiedebergs Arch Pharmacol. 2015;388(9):905-919. https://doi.org/10.1007/s00210-015-1124-3Tian W, Jiang W, Yao J, et al. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. J Med Virol. 2020;92(10):1875-1883. https://doi.org/10.1002/jmv.26050Tian W, Jiang W, Yao J, et al. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. J Med Virol. 2020;92(10):1875-1883. https://doi.org/10.1002/jmv.26050Дедов И.И., Мокрышева Н.Г., Шестакова М.В. и др. Контроль гликемии и выбор антигипергликемической терапии у пациентов с сахарным диабетом 2 типа и COVID-19: консенсусное решение совета экспертов Российской ассоциации эндокринологов // Сахарный диабет. 2022. — Т. 25. — №1. — С. 27-49. https://doi.org/10.14341/DM12873[Dedov II, Mokrysheva NG, Shestakova MV, et al. Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists. Diabetes mellitus. 2022;25(1):27-49. (In Russ).. https://doi.org/10.14341/DM12873Markova T, Stas M, Anchutina A. 768-P: Effect of Dulaglutide Therapy Initiation on the Course of Coronavirus Infection and the Dynamics of Inflammatory Markers in Hospitalized Patients with Type 2 Diabetes. Diabetes. 2023;72 (Supplement_1): 768–P. https://doi.org/10.2337/db23-768-PMarkova T, Stas M, Anchutina A. 768-P: Effect of Dulaglutide Therapy Initiation on the Course of Coronavirus Infection and the Dynamics of Inflammatory Markers in Hospitalized Patients with Type 2 Diabetes. Diabetes. 2023;72 (Supplement_1): 768–P. https://doi.org/10.2337/db23-768-PМаркова Т.Н., Стас М.С., Анчутина А.А., Чибисова В.В. Оценка влияния инициации терапии агонистами рецепторов глюкагоноподобного пептида 1 на исходы у пациентов с сахарным диабетом 2 типа, госпитализированных с коронавирусной инфекцией // Сахарный диабет и ожирение — неинфекционные междисциплинарные пандемии XXI века: сборник тезисов IX (XXVIII) Национального диабетологического конгресса с международным участием. — Москва, 05–08 сентября 2022 года / ОО «Российская ассоциация эндокринологов»; ФГБУ «НМИЦ эндокринологии» Минздрава России. — Москва: Б. и., 2022. — С. 132. https://doi.org/10.14341/Conf05-08.09.22-132. – EDN YXATUPMarkova TN, Stas MS, Anchutina AA, Chibisova VV. Assessment of the effect of initiation of therapy with glucagon-like peptide 1 receptor agonists on outcomes in patients with type 2 diabetes hospitalized with coronavirus infection// Diabetes mellitus and obesity – non-infectious interdisciplinary pandemics of the XXI century: collection of theses IX (XXVIII) of the National Diabetological Congress with international participation, Moscow, 05-08 September 2022 / NGO “Russian Association of Endocrinologists”; FSBI “NMIC of Endocrinology” of the Ministry of Health of Russia. — Moscow: B. I., 2022. — p. 132 — https://doi.org/10.14341/Conf05-08.09.22-132. – EDN YXATUP

The authors declare that there are no conflicts of interest present.